Association of MDR1 and ERCC1 polymorphisms with response and toxicity to cisplatin-based chemotherapy in non-small-cell lung cancer patients

International Journal of Hygiene and Environmental Health

Volumn 213, Issue 2, 2010, Pages 140-145

  Chen, Songjian ^a   Huo, Xia ^a   Lin, Yi ^b   Ban, Hao ^a   Lin, Yincheng ^b   Li, Weiqiu ^a   Zhang, Bao ^a   Au, William W ^c   Xu, Xijin ^a  

^a SHANTOU UNIVERSITY MEDICAL COLLEGE   (China)

^b Cancer Hospital   (China)

^c SHANTOU UNIVERSITY   (China)

Author keywords

Cisplatin; Drug resistance; ERCC1; MDR1; Non small cell lung cancer; Single nucleotide polymorphism

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DNA BINDING PROTEIN; ENDONUCLEASE; ERCC1 PROTEIN, HUMAN; GLYCOPROTEIN P;

ADULT; AGED; ARTICLE; CHEMICALLY INDUCED DISORDER; DRUG RESISTANCE; FEMALE; GASTROINTESTINAL DISEASE; GENE FREQUENCY; GENETICS; HAPLOTYPE; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MALE; MIDDLE AGED; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; ENDONUCLEASES; FEMALE; GASTROINTESTINAL DISEASES; GENE FREQUENCY; HAPLOTYPES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; P-GLYCOPROTEIN; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 77649238161     PISSN: 14384639     EISSN: 1618131X     Source Type: Journal    
DOI: 10.1016/j.ijheh.2010.01.004     Document Type: Article

References (29)

1. Bunn P.A., Bunn T.L., and Costich J.F. Chemotherapy for advanced non-small-cell lung cancer: who, what, when, why?. J. Clin. Oncol. 20 (2002) 23S-33S
2. Duffaud F., and Therasse P. New guidelines to evaluate the response to treatment in solid tumors. Bull. Cancer 87 (2000) 881-886
3. Furuta T., Ueda T., Aune G., Sarasin A., Kraemer K.H., and Pommier Y. Transcription-coupled nucleotide excision repair as a determinant of cisplatin sensitivity of human cells. Cancer Res. 62 (2002) 4899-4902
4. Gurubhagavatula S., Liu G., Park S., Zhou W., Su L., Wain J.C., Lynch T.J., Neuberg D.S., and Christiani D.C. XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. J. Clin. Oncol. 22 (2004) 2594-2601
5. Hoffmeyer S., Burk O., von Richter O., Arnold H.P., Brockmoller J., Johne A., Cascorbi I., Gerloff T., Roots I., Eichelbaum M., and Brinkmann U. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl. Acad. Sci. USA 97 (2000) 3473-3478
6. Isla D., Sarries C., Rosell R., Alonso G., Domine M., Taron M., Lopez-Vivanco G., Camps C., Botia M., Nunez L., Sanchez-Ronco M., Sanchez J.J., Lopez-Brea M., Barneto I., Paredes A., Medina B., Artal A., and Lianes P. Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer. Ann. Oncol. 15 (2004) 1194-1203
7. Ito S., Ieiri I., Tanabe M., Suzuki A., Higuchi S., and Otsubo K. Polymorphism of the ABC transporter genes, MDR1, MRP1 and MRP2/cMOAT, in healthy Japanese subjects. Pharmacogenetics. 11 (2001) 175-184
8. Kim R.B., Leake B.F., Choo E.F., Dresser G.K., Kubba S.V., Schwarz U.I., Taylor A., Xie J., McKinsey H.G., Zhou S., Lan L.B., Schuetz J.D., Schuetz E.G., and Wilkinson G.R. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin. Pharmacol. Ther. 70 (2001) 189-199
9. Lord R.V., Brabender J., Gandara D., Alberola V., Camps C., Domine M., Cardenal F., Sanchez J.M., Gumerlock P.H., Taron M., Sanchez J.J., Danenberg K.D., Danenberg P.V., and Rosell R. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin. Cancer Res. 8 (2002) 2286-2291
10. Olaussen K.A., Dunant A., Fouret P., Brambilla E., Andre F., Haddad V., Taranchon E., Filipits M., Pirker R., Popper H.H., Stahel R., Sabatier L., Pignon J.P., Tursz T., Le Chevalier T., and Soria J.C. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N. Engl. J. Med. 355 (2006) 983-991
11. Pan J.H., Han J.X., Wu J.M., Huang H.N., Yu Q.Z., and Sheng L.J. MDR1 single nucleotide polymorphism G2677T/A and haplotype are correlated with response to docetaxel-cisplatin chemotherapy in patients with non-small-cell lung cancer. Respiration 78 (2009) 49-55
12. Pan J.H., Han J.X., Wu J.M., Sheng L.J., Huang H.N., and Yu Q.Z. MDR1 single nucleotide polymorphisms predict response to vinorelbine-based chemotherapy in patients with non-small cell lung cancer. Respiration 75 (2008) 380-385
13. Price N. Impact of genetic polymorphisms in DNA repair enzymes on drug resistance in lung cancer. Clin. Lung Cancer 6 (2004) 79-82
14. Rosell R., Lord R.V., Taron M., and Reguart N. DNA repair and cisplatin resistance in non-small-cell lung cancer. Lung Cancer. 38 (2002) 217-227
15. Saito K., Miyake S., Moriya H., Yamazaki M., Itoh F., Imai K., Kurosawa N., Owada E., and Miyamoto A. Detection of the four sequence variations of MDR1 gene using TaqMan MGB probe based real-time PCR and haplotype analysis in healthy Japanese subjects. Clin. Biochem. 36 (2003) 511-518
16. Sakaeda T., Nakamura T., and Okumura K. MDR1 genotype-related pharmacokinetics and pharmacodynamics. Biol. Pharm. Bull. 25 (2002) 1391-1400
17. Shi Y.Y., and He L. SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci. Cell Res. 15 (2005) 97-98
18. Smith S., Su D., Rigault de la Longrais I.A., Schwartz P., Puopolo M., Rutherford T.J., Mor G., Yu H., and Katsaros D. ERCC1 genotype and phenotype in epithelial ovarian cancer identify patients likely to benefit from paclitaxel treatment in addition to platinum-based therapy. J. Clin. Oncol. 25 (2007) 5172-5179
19. Spiro S.G., and Silvestri G.A. The treatment of advanced non-small cell lung cancer. Curr. Opin. Pulm. Med. 11 (2005) 287-291
20. Su D., Ma S., Liu P., Jiang Z., Lu W., Zhang Y., Deng Q., Smith S., and Yu H. Genetic polymorphisms and treatment response in advanced non-small cell lung cancer. Lung Cancer 56 (2007) 281-288
21. Takara K., Sakaeda T., and Okumura K. An update on overcoming MDR1-mediated multidrug resistance in cancer chemotherapy. Curr. Pharm. Des. 12 (2006) 273-286
22. Tanabe M., Ieiri I., Nagata N., Inoue K., Ito S., Kanamori Y., Takahashi M., Kurata Y., Kigawa J., Higuchi S., Terakawa N., and Otsubo K. Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J. Pharmacol. Exp. Ther. 297 (2001) 1137-1143
23. Thiebaut F., Tsuruo T., Hamada H., Gottesman M.M., Pastan I., and Willingham M.C. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc. Natl. Acad. Sci. USA 84 (1987) 7735-7738
24. Tibaldi C., Giovannetti E., Vasile E., Mey V., Laan A.C., Nannizzi S., Di Marsico R., Antonuzzo A., Orlandini C., Ricciardi S., Del Tacca M., Peters G.J., Falcone A., and Danesi R. Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin. Cancer Res. 14 (2008) 1797-1803
25. Tripsianes K., Folkers G., Ab E., Das D., Odijk H., Jaspers N.G., Hoeijmakers J.H., Kaptein R., and Boelens R. The structure of the human ERCC1/XPF interaction domains reveals a complementary role for the two proteins in nucleotide excision repair. Structure 13 (2005) 1849-1858
26. Viktorsson K., De Petris L., and Lewensohn R. The role of p53 in treatment responses of lung cancer. Biochem. Biophys. Res. Commun. 331 (2005) 868-880
27. WHO. WHO Handbook for Reporting Results of Cancer Treatment. WHO Offset Publication no. 48 (1979), World Health Organization, Geneva, Switzerland
28. Yu J.J., Mu C., Lee K.B., Okamoto A., Reed E.L., Bostick-Bruton F., Mitchell K.C., and Reed E. A nucleotide polymorphism in ERCC1 in human ovarian cancer cell lines and tumor tissues. Mutat. Res. 382 (1997) 13-20
29. Zienolddiny S., Campa D., Lind H., Ryberg D., Skaug V., Stangeland L., Phillips D.H., Canzian F., and Haugen A. Polymorphisms of DNA repair genes and risk of non-small cell lung cancer. Carcinogenesis 27 (2006) 560-567